News
SNGX
0.3200
-0.40%
-0.0013
Weekly Report: what happened at SNGX last week (1102-1106)?
Weekly Report · 3d ago
Soligenix Q3 EPS $(0.05) Beats $(0.10) Estimate
Benzinga · 6d ago
Soligenix GAAP EPS of -$0.05 beats by $0.07
Seeking Alpha · 6d ago
*Soligenix 3Q Research and Development Expenses $400,000 >SNGX
Dow Jones · 6d ago
Press Release: Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
Dow Jones · 6d ago
Weekly Report: what happened at SNGX last week (1026-1030)?
Weekly Report · 11/02 09:13
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg
Benzinga · 10/27 12:39
Weekly Report: what happened at SNGX last week (1019-1023)?
Weekly Report · 10/26 09:12
Weekly Report: what happened at SNGX last week (1012-1016)?
Weekly Report · 10/19 09:12
Weekly Report: what happened at SNGX last week (1005-1009)?
Weekly Report · 10/12 09:13
Weekly Report: what happened at SNGX last week (0928-1002)?
Weekly Report · 10/05 09:13
Weekly Report: what happened at SNGX last week (0921-0925)?
Weekly Report · 09/28 09:13
Soligenix Shareholders Approve Governance and Capital Changes
TipRanks · 09/21 21:21
Weekly Report: what happened at SNGX last week (0914-0918)?
Weekly Report · 09/21 09:13
Weekly Report: what happened at SNGX last week (0907-0911)?
Weekly Report · 09/14 09:13
Weekly Report: what happened at SNGX last week (0831-0904)?
Weekly Report · 09/07 09:12
Weekly Report: what happened at SNGX last week (0824-0828)?
Weekly Report · 08/31 09:13
Weekly Report: what happened at SNGX last week (0817-0821)?
Weekly Report · 08/24 09:14
Weekly Report: what happened at SNGX last week (0810-0814)?
Weekly Report · 08/17 09:14
Weekly Report: what happened at SNGX last week (0803-0807)?
Weekly Report · 08/10 09:13
More
Webull provides a variety of real-time SNGX stock news. You can receive the latest news about Soligenix Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).